We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MMSI Expands Oncology Offering With View Point Medical Acquisition
Read MoreHide Full Article
Key Takeaways
MMSI acquired View Point Medical for $140M to expand tumor detection and oncology capabilities.
The deal adds ultrasound-based tech to MMSI's SCOUT platform, improving tumor localization accuracy.
MMSI expects near-term EPS dilution but projects strong revenue growth and accretion by 2027.
Merit Medical Systems, Inc. (MMSI - Free Report) recently announced the acquisition of View Point Medical, Inc., with the intent to expand its therapeutic oncology portfolio and strengthen its capabilities in tumor detection and localization in breast and soft tissue cancers.
The total transaction value stands at approximately $140 million, including assumed liabilities and an upfront cash payment of $90 million, along with two deferred payments of $25 million each, scheduled within the first and second anniversaries of the closing date. Following the merger, View Point Medical became a wholly owned subsidiary of Merit Medical.
Per management, the acquisition strengthens MMSI’s oncology portfolio by enhancing its capabilities in the precise detection and localization of breast and soft tissue tumors. The company has established a strong leadership position in wire-free, non-radioactive breast localization, built upon its SCOUT platform, which leverages radar technology for precision and accuracy. The addition of View Point Medical’s ultrasound-based innovation further expands these capabilities, enabling more lesions to be identified at the biopsy stage, addressing an estimated 1.3 million procedures each year in the United States. MMSI plans to provide more details about the acquisition during its first-quarter investor conference call.
MMSI Stock Trend Following the News
Following the announcement, shares of MMSI lost 1.0% at yesterday’s closing. In the year-to-date period, the stock lost 22.6% compared with the industry’s 2.9% decline and the S&P 500’s 4.9% fall.
In the long run, Merit Medical stands to gain strong strategic and financial benefits from acquiring View Point Medical. The deal strengthens its therapeutic oncology portfolio, enhancing breast tumor localization through the combined SCOUT System and OneMark System. This integration can reduce additional procedures and improve patient outcomes, supporting long-term demand. While earnings face short-term pressure in 2026, the acquisition is expected to drive strong revenue growth and high margins, and become accretive to non-GAAP earnings by 2027, reinforcing Merit Medical’s leadership and growth trajectory in oncology solutions.
MMSI currently has a market capitalization of $4.10 billion.
Image Source: Zacks Investment Research
More on the Acquisition
Based in Carlsbad, CA, View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers — innovative tools designed to enhance tumor localization. The OneMark system, cleared by the FDA, combines a surgical detection console with ultrasound-enhanced markers that remain visible across commonly used imaging modalities while minimizing interference with imaging studies. When integrated with MMSI’s SCOUT platform, the combined technologies offer physicians greater flexibility in localizing tissue during the initial biopsy and eliminate the need for an additional procedure to mark the tumor site before surgery.
Financially, the acquisition is expected to have a modest near-term impact. From April 1, 2026, through Dec. 31, 2026, the deal is projected to generate between $2 million and $4 million in revenues while diluting non-GAAP earnings per share by about 5 cents. This dilution reflects around $2 million in reduced interest income due to the use of cash for the transaction and excludes $5.3 million in non-cash, non-recurring transaction-related expenses.
However, the long-term outlook appears promising. By 2027, revenue contribution is expected to grow to $14 million-$16 million, supported by projected annual sales growth of at least 20% and strong non-GAAP gross margins of around 70%. The deal is expected to become accretive to non-GAAP earnings per share in 2027 and to GAAP earnings thereafter.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the cancer diagnostics market is valued at $184.96 billion in 2026 and is expected to witness a CAGR of 8.3% through 2035.
Factors like the rising cancer incidence and aging population, technological advancements in diagnostics, emphasis on early detection, high healthcare spending & R&D are driving market growth.
Other News
Merit Medical recently announced the U.S. launch of its Resilience Through-the-Scope Esophageal Stent. This latest addition expands the company’s Endoscopy portfolio, enhancing its range of treatment options for esophageal conditions. The Resilience stent is designed for use in patients with esophageal fistulas and strictures, including those caused by malignant tumors.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Inspire Medical Systems (INSP - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Inspire Medical Systems, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted EPS of $1.65, beating the Zacks Consensus Estimate by 139.1%. Revenues of $269.1 million were in line with the Zacks Consensus Estimate.
INSP has an estimated long-term earnings growth rate of 10.6% compared with the industry’s 29.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 185.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MMSI Expands Oncology Offering With View Point Medical Acquisition
Key Takeaways
Merit Medical Systems, Inc. (MMSI - Free Report) recently announced the acquisition of View Point Medical, Inc., with the intent to expand its therapeutic oncology portfolio and strengthen its capabilities in tumor detection and localization in breast and soft tissue cancers.
The total transaction value stands at approximately $140 million, including assumed liabilities and an upfront cash payment of $90 million, along with two deferred payments of $25 million each, scheduled within the first and second anniversaries of the closing date. Following the merger, View Point Medical became a wholly owned subsidiary of Merit Medical.
Per management, the acquisition strengthens MMSI’s oncology portfolio by enhancing its capabilities in the precise detection and localization of breast and soft tissue tumors. The company has established a strong leadership position in wire-free, non-radioactive breast localization, built upon its SCOUT platform, which leverages radar technology for precision and accuracy. The addition of View Point Medical’s ultrasound-based innovation further expands these capabilities, enabling more lesions to be identified at the biopsy stage, addressing an estimated 1.3 million procedures each year in the United States. MMSI plans to provide more details about the acquisition during its first-quarter investor conference call.
MMSI Stock Trend Following the News
Following the announcement, shares of MMSI lost 1.0% at yesterday’s closing. In the year-to-date period, the stock lost 22.6% compared with the industry’s 2.9% decline and the S&P 500’s 4.9% fall.
In the long run, Merit Medical stands to gain strong strategic and financial benefits from acquiring View Point Medical. The deal strengthens its therapeutic oncology portfolio, enhancing breast tumor localization through the combined SCOUT System and OneMark System. This integration can reduce additional procedures and improve patient outcomes, supporting long-term demand. While earnings face short-term pressure in 2026, the acquisition is expected to drive strong revenue growth and high margins, and become accretive to non-GAAP earnings by 2027, reinforcing Merit Medical’s leadership and growth trajectory in oncology solutions.
MMSI currently has a market capitalization of $4.10 billion.
Image Source: Zacks Investment Research
More on the Acquisition
Based in Carlsbad, CA, View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers — innovative tools designed to enhance tumor localization. The OneMark system, cleared by the FDA, combines a surgical detection console with ultrasound-enhanced markers that remain visible across commonly used imaging modalities while minimizing interference with imaging studies. When integrated with MMSI’s SCOUT platform, the combined technologies offer physicians greater flexibility in localizing tissue during the initial biopsy and eliminate the need for an additional procedure to mark the tumor site before surgery.
Financially, the acquisition is expected to have a modest near-term impact. From April 1, 2026, through Dec. 31, 2026, the deal is projected to generate between $2 million and $4 million in revenues while diluting non-GAAP earnings per share by about 5 cents. This dilution reflects around $2 million in reduced interest income due to the use of cash for the transaction and excludes $5.3 million in non-cash, non-recurring transaction-related expenses.
However, the long-term outlook appears promising. By 2027, revenue contribution is expected to grow to $14 million-$16 million, supported by projected annual sales growth of at least 20% and strong non-GAAP gross margins of around 70%. The deal is expected to become accretive to non-GAAP earnings per share in 2027 and to GAAP earnings thereafter.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the cancer diagnostics market is valued at $184.96 billion in 2026 and is expected to witness a CAGR of 8.3% through 2035.
Factors like the rising cancer incidence and aging population, technological advancements in diagnostics, emphasis on early detection, high healthcare spending & R&D are driving market growth.
Other News
Merit Medical recently announced the U.S. launch of its Resilience Through-the-Scope Esophageal Stent. This latest addition expands the company’s Endoscopy portfolio, enhancing its range of treatment options for esophageal conditions. The Resilience stent is designed for use in patients with esophageal fistulas and strictures, including those caused by malignant tumors.
Merit Medical Systems, Inc. Price
Merit Medical Systems, Inc. price | Merit Medical Systems, Inc. Quote
MMSI’s Zacks Rank & Key Picks
Currently, MMSI carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Inspire Medical Systems (INSP - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Inspire Medical Systems, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted EPS of $1.65, beating the Zacks Consensus Estimate by 139.1%. Revenues of $269.1 million were in line with the Zacks Consensus Estimate.
INSP has an estimated long-term earnings growth rate of 10.6% compared with the industry’s 29.7% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 185.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.